EA201692001A1 - Способ получения amg 416 - Google Patents

Способ получения amg 416

Info

Publication number
EA201692001A1
EA201692001A1 EA201692001A EA201692001A EA201692001A1 EA 201692001 A1 EA201692001 A1 EA 201692001A1 EA 201692001 A EA201692001 A EA 201692001A EA 201692001 A EA201692001 A EA 201692001A EA 201692001 A1 EA201692001 A1 EA 201692001A1
Authority
EA
Eurasian Patent Office
Prior art keywords
amg
obtaining
receptor
shpt
mbd
Prior art date
Application number
EA201692001A
Other languages
English (en)
Other versions
EA032597B1 (ru
Inventor
Ерун Беземер
Ин ЧЭНЬ
Ричард Крокетт
Кевин Кроссли
Шен Цуй
Лян Хуан
Сиан Джонс
Ашер Лоуэр
Кришнакумар Ранганатхан
Original Assignee
Эмджен Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54241346&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201692001(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Эмджен Инк. filed Critical Эмджен Инк.
Publication of EA201692001A1 publication Critical patent/EA201692001A1/ru
Publication of EA032597B1 publication Critical patent/EA032597B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/02—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length in solution
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C07K1/1075—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of amino acids or peptide residues
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A61P5/20—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of PTH

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Glass Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Предлагается способ получения AMG 416 или его фармацевтически приемлемой соли. AMG 416 представляет собой синтетический, состоящий из восьми аминокислот селективный пептидный агонист кальцийчувствительного рецептора. Он был разработан в качестве внутривенного лечения вторичного гиперпаратиреоза (SHPT) гемодиализных больных с хроническим заболеванием почек - минеральным и костным расстройством (CKD-MBD).
EA201692001A 2014-04-03 2015-04-03 Способ получения amg 416 EA032597B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461974899P 2014-04-03 2014-04-03
PCT/US2015/024347 WO2015154031A1 (en) 2014-04-03 2015-04-03 Method for preparing amg 416

Publications (2)

Publication Number Publication Date
EA201692001A1 true EA201692001A1 (ru) 2017-02-28
EA032597B1 EA032597B1 (ru) 2019-06-28

Family

ID=54241346

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201692001A EA032597B1 (ru) 2014-04-03 2015-04-03 Способ получения amg 416

Country Status (27)

Country Link
US (3) US10407464B2 (ru)
EP (3) EP3708576B1 (ru)
JP (1) JP6710158B2 (ru)
KR (1) KR102397271B1 (ru)
CN (1) CN106795201A (ru)
AU (1) AU2015240527B2 (ru)
BR (1) BR112016022868A2 (ru)
CA (1) CA2944194C (ru)
CL (1) CL2016002513A1 (ru)
CY (1) CY1123100T1 (ru)
DK (1) DK3126373T3 (ru)
EA (1) EA032597B1 (ru)
ES (2) ES2786225T3 (ru)
HR (1) HRP20200527T1 (ru)
HU (1) HUE048489T2 (ru)
IL (1) IL248059B2 (ru)
LT (1) LT3126373T (ru)
MA (2) MA52906A (ru)
ME (1) ME03781B (ru)
MX (1) MX2016012965A (ru)
PL (1) PL3126373T3 (ru)
PT (1) PT3126373T (ru)
RS (1) RS60187B1 (ru)
SG (1) SG11201608176VA (ru)
SI (1) SI3126373T1 (ru)
WO (1) WO2015154031A1 (ru)
ZA (1) ZA201606844B (ru)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2916222C (en) 2013-06-28 2021-05-18 Amgen Inc. Stable liquid formulation of amg 416 (etelcalcetide)
CN106795201A (zh) 2014-04-03 2017-05-31 美国安进公司 用于制备amg416的方法
CN106928320B (zh) * 2015-12-31 2021-01-15 深圳翰宇药业股份有限公司 一种合成Etelcalcetide的方法
CN106928321B (zh) * 2015-12-31 2019-07-26 深圳翰宇药业股份有限公司 一种合成Etelcalcetide的方法
JP6991196B2 (ja) * 2016-03-23 2022-02-03 バッヘン・ホールディング・アクチエンゲゼルシャフト グルカゴン様ペプチドを製造するための方法
US10858390B2 (en) * 2016-09-02 2020-12-08 Cem Corporation Use of excess carbodiimide for peptide synthesis at elevated temperatures
CN108101959B (zh) * 2016-11-24 2021-07-09 四川科伦药物研究院有限公司 一种制备高纯度多肽或其类似物的方法
CN106928171B (zh) * 2017-05-03 2019-08-13 成都郑源生化科技有限公司 Fmoc-Arg（Pbf）-OH的合成方法
TW201915009A (zh) * 2017-10-03 2019-04-16 中化合成生技股份有限公司 合成依特卡肽（Ｅｔｅｌｃａｌｃｅｔｉｄｅ）或其鹽類之方法
CN110498835B (zh) * 2018-05-17 2021-06-08 深圳翰宇药业股份有限公司 一种合成etelcalcetide的方法
CN109280078B (zh) * 2018-10-30 2019-06-25 成都诺和晟泰生物科技有限公司 一种制备维拉卡肽的方法
CN112062811B (zh) * 2019-06-10 2022-03-25 深圳翰宇药业股份有限公司 一种维拉卡肽的合成方法
EP4021920A4 (en) * 2019-08-26 2023-08-16 Auro Peptides LTD IMPROVED PROCESS FOR THE PREPARATION OF ETELCALKETIDE HYDROCHLORIDE
EP3875466A1 (en) * 2020-03-05 2021-09-08 Fresenius Kabi iPSUM S.r.l. Process for the synthesis of etelcalcetide
KR20230019120A (ko) 2020-06-03 2023-02-07 추가이 세이야쿠 가부시키가이샤 고난도 서열의 효율적 펩티드 축합법
CN111925415A (zh) * 2020-08-10 2020-11-13 海南中和药业股份有限公司 一种维拉卡肽杂质的制备方法
TWI792442B (zh) * 2021-07-23 2023-02-11 建誼生技股份有限公司 依特卡肽鹽酸鹽之製造方法
CN114524860A (zh) * 2021-12-29 2022-05-24 深圳翰宇药业股份有限公司 一种Etelcalcetide的合成方法及其应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3941763A (en) 1975-03-28 1976-03-02 American Home Products Corporation PGlu-D-Met-Trp-Ser-Tyr-D-Ala-Leu-Arg-Pro-Gly-NH2 and intermediates
EP0339695A3 (en) 1988-04-29 1990-05-30 Stichting Voor De Technische Wetenschappen A process for preparing an antigenic or immunogenic conjugate as well as the use of such conjugates
SE9603465D0 (sv) 1996-09-23 1996-09-23 Astra Ab New compounds
NO311807B1 (no) 1999-03-04 2002-01-28 Bionor Immuno As HIV-peptider, antigener, vaksinepreparater, immunoassay- testsett og en metode for påvisning av antistoffer fremkalt av HIV
JP5473925B2 (ja) 2007-10-27 2014-04-16 コーデン ファーマ コロラド インコーポレイテッド 固相および溶液相の組み合わせ技法を使用するインスリン分泌性ペプチドの合成
CN101250172B (zh) 2008-03-07 2012-05-02 上海瀚鸿化工科技有限公司 精氨酸双保护制备工艺
CA2761265C (en) 2009-05-06 2017-12-19 Mallinckrodt Llc Solid support for fmoc-solid phase synthesis of peptide acids
SG10201406921SA (en) 2009-07-29 2014-11-27 Kai Pharmaceuticals Inc Therapeutic agents for reducing parathyroid hormone levels
WO2011133346A1 (en) * 2010-04-21 2011-10-27 Pharmacofore, Inc. Peripheral opioid agonists and peripheral opioid antagonists
US20140024592A1 (en) * 2010-09-08 2014-01-23 Howard Florey Institute Of Experimental Physiology And Medicine Modified Relaxin Polypeptides
WO2013042129A1 (en) 2011-09-23 2013-03-28 Natco Pharma Limited Improved process for preparation of bivalirudin
CA2916222C (en) 2013-06-28 2021-05-18 Amgen Inc. Stable liquid formulation of amg 416 (etelcalcetide)
CN106795201A (zh) 2014-04-03 2017-05-31 美国安进公司 用于制备amg416的方法
CN105504012A (zh) * 2014-09-30 2016-04-20 深圳翰宇药业股份有限公司 一种多肽的制备方法
CN107434820A (zh) * 2017-08-07 2017-12-05 南京工业大学 一种维拉卡肽的合成方法

Also Published As

Publication number Publication date
US10407464B2 (en) 2019-09-10
US20190352336A1 (en) 2019-11-21
KR102397271B1 (ko) 2022-05-16
CA2944194C (en) 2022-04-19
CL2016002513A1 (es) 2018-03-23
PL3126373T3 (pl) 2020-07-27
EP4219526A2 (en) 2023-08-02
HRP20200527T1 (hr) 2020-06-26
MA39628B1 (fr) 2020-05-29
RS60187B1 (sr) 2020-06-30
ES2786225T3 (es) 2020-10-09
JP2017511332A (ja) 2017-04-20
ES2943671T3 (es) 2023-06-15
SG11201608176VA (en) 2016-10-28
HUE048489T2 (hu) 2020-07-28
IL248059A0 (en) 2016-11-30
EP4219526A3 (en) 2023-08-30
CN106795201A (zh) 2017-05-31
EP3126373A1 (en) 2017-02-08
DK3126373T3 (da) 2020-05-04
AU2015240527A1 (en) 2016-10-20
EA032597B1 (ru) 2019-06-28
EP3126373A4 (en) 2018-06-20
MA52906A (fr) 2021-04-21
US11377474B2 (en) 2022-07-05
IL248059B1 (en) 2023-06-01
LT3126373T (lt) 2020-05-11
JP6710158B2 (ja) 2020-06-17
US20170190739A1 (en) 2017-07-06
WO2015154031A1 (en) 2015-10-08
MX2016012965A (es) 2017-07-06
IL248059B2 (en) 2023-10-01
AU2015240527B2 (en) 2019-09-26
PT3126373T (pt) 2020-04-24
BR112016022868A2 (pt) 2018-07-03
ME03781B (me) 2021-04-20
ZA201606844B (en) 2018-07-25
KR20170026326A (ko) 2017-03-08
EP3708576A1 (en) 2020-09-16
SI3126373T1 (sl) 2020-06-30
US20230099078A1 (en) 2023-03-30
EP3708576B1 (en) 2023-02-22
CA2944194A1 (en) 2015-10-08
CY1123100T1 (el) 2021-10-29
EP3126373B1 (en) 2020-03-04

Similar Documents

Publication Publication Date Title
EA201692001A1 (ru) Способ получения amg 416
EA201990293A1 (ru) Мультиспецифичные антитела против cd40 и cd137
EA201791420A1 (ru) Соединения триазолопиримидина и их применения
CL2016002679A1 (es) Métodos para mejorar o acelerar la recuperación física después la cirugía por fractura de cadera.
CL2017003427A1 (es) Anticuerpos para cd40
CY1122695T1 (el) Αλας toy omecamtiv mecarbil και διαδικασια για την παρασκευη αλατος
EA201992474A3 (ru) Агонисты 5ht для лечения нарушений
EA201692436A1 (ru) Медицинское применение
EA201790932A1 (ru) Дозировка и введение нефукозилированных анти-cd40 антител
NZ723858A (en) Anti-human ox40l antibodies, uses & methods
EA201892119A1 (ru) Лекарственный препарат, полученный путем комбинирования агониста fxr и arb
EA201391171A1 (ru) Формы рифаксимина и их применение
EA201890442A1 (ru) Получение фоторецепторов для лечения заболеваний сетчатки
MX2015013066A (es) Usos terapéuticos para anticuerpos contra vegfr1.
EA201790432A1 (ru) Зонды для визуализации белка хантингтина
MX2017000635A (es) Inhibidores del canal de potasio medular externo renal.
TN2015000356A1 (en) Bicyclic compounds
MX2017001855A (es) Compuestos biciclicos sustituidos.
MX2017000634A (es) Inhibidores del canal de potasio medularmente externo renal.
PH12016500042A1 (en) Stabilized pharmaceutical dosage forms comprising atrasentan
EA201692482A1 (ru) Способы лечения заболеваний антителами, которые связывают рецептор колониестимулирующего фактора 1 (csf1r)
MX2019014090A (es) Métodos para el tratamiento de la reservoritis crónica.
EA201692564A1 (ru) Комбинированная терапия
RU2014106575A (ru) Способ профилактики кровотечения при миомэктомии
EA201691218A1 (ru) Агонисты a1-аденозиновых рецепторов в качестве лекарственного средства для лечения заболеваний почек

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM